391 related articles for article (PubMed ID: 33634529)
1. Reactive astrocytes as treatment targets in Alzheimer's disease-Systematic review of studies using the APPswePS1dE9 mouse model.
Smit T; Deshayes NAC; Borchelt DR; Kamphuis W; Middeldorp J; Hol EM
Glia; 2021 Aug; 69(8):1852-1881. PubMed ID: 33634529
[TBL] [Abstract][Full Text] [Related]
2. Vitamin D Reduces GABA-Positive Astrocytes in the 5xFAD Mouse Model of Alzheimer's Disease.
Kang J; Park M; Kim T
J Alzheimers Dis; 2024; 97(4):1939-1950. PubMed ID: 38339931
[TBL] [Abstract][Full Text] [Related]
3. The neuroprotective N-terminal amyloid-β core hexapeptide reverses reactive gliosis and gliotoxicity in Alzheimer's disease pathology models.
Lantz MJ; Roberts AM; Delgado DD; Nichols RA
J Neuroinflammation; 2023 May; 20(1):129. PubMed ID: 37245024
[TBL] [Abstract][Full Text] [Related]
4. Retinal macroglia changes in a triple transgenic mouse model of Alzheimer's disease.
Edwards MM; Rodríguez JJ; Gutierrez-Lanza R; Yates J; Verkhratsky A; Lutty GA
Exp Eye Res; 2014 Oct; 127():252-60. PubMed ID: 25149907
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of human S100B exacerbates cerebral amyloidosis and gliosis in the Tg2576 mouse model of Alzheimer's disease.
Mori T; Koyama N; Arendash GW; Horikoshi-Sakuraba Y; Tan J; Town T
Glia; 2010 Feb; 58(3):300-14. PubMed ID: 19705461
[TBL] [Abstract][Full Text] [Related]
6. Regulatory T cells decrease C3-positive reactive astrocytes in Alzheimer-like pathology.
Stym-Popper G; Matta K; Chaigneau T; Rupra R; Demetriou A; Fouquet S; Dansokho C; Toly-Ndour C; Dorothée G
J Neuroinflammation; 2023 Mar; 20(1):64. PubMed ID: 36890536
[TBL] [Abstract][Full Text] [Related]
7. The difference in gliosis induced by β-amyloid and Tau treatments in astrocyte cultures derived from senescence accelerated and normal mouse strains.
Lü L; Mak YT; Fang M; Yew DT
Biogerontology; 2009 Dec; 10(6):695-710. PubMed ID: 19221889
[TBL] [Abstract][Full Text] [Related]
8. Astroglial Responses to Amyloid-Beta Progression in a Mouse Model of Alzheimer's Disease.
Olsen M; Aguilar X; Sehlin D; Fang XT; Antoni G; Erlandsson A; Syvänen S
Mol Imaging Biol; 2018 Aug; 20(4):605-614. PubMed ID: 29297157
[TBL] [Abstract][Full Text] [Related]
9. Astrocytic palmitoylethanolamide pre-exposure exerts neuroprotective effects in astrocyte-neuron co-cultures from a triple transgenic mouse model of Alzheimer's disease.
Beggiato S; Cassano T; Ferraro L; Tomasini MC
Life Sci; 2020 Sep; 257():118037. PubMed ID: 32622942
[TBL] [Abstract][Full Text] [Related]
10. KCa3.1 constitutes a pharmacological target for astrogliosis associated with Alzheimer's disease.
Yi M; Yu P; Lu Q; Geller HM; Yu Z; Chen H
Mol Cell Neurosci; 2016 Oct; 76():21-32. PubMed ID: 27567685
[TBL] [Abstract][Full Text] [Related]
11. Astrocyte Reactivity in Alzheimer's Disease: Therapeutic Opportunities to Promote Repair.
Mirzaei N; Davis N; Chau TW; Sastre M
Curr Alzheimer Res; 2022; 19(1):1-15. PubMed ID: 34719372
[TBL] [Abstract][Full Text] [Related]
12. A Role of Low-Density Lipoprotein Receptor-Related Protein 4 (LRP4) in Astrocytic Aβ Clearance.
Zhang H; Chen W; Tan Z; Zhang L; Dong Z; Cui W; Zhao K; Wang H; Jing H; Cao R; Kim C; Safar JG; Xiong WC; Mei L
J Neurosci; 2020 Jul; 40(28):5347-5361. PubMed ID: 32457076
[TBL] [Abstract][Full Text] [Related]
13. Quantitative proteomics reveals that PEA15 regulates astroglial Aβ phagocytosis in an Alzheimer's disease mouse model.
Lv J; Ma S; Zhang X; Zheng L; Ma Y; Zhao X; Lai W; Shen H; Wang Q; Ji J
J Proteomics; 2014 Oct; 110():45-58. PubMed ID: 25108202
[TBL] [Abstract][Full Text] [Related]
14. Physiological expression of mutated TAU impaired astrocyte activity and exacerbates β-amyloid pathology in 5xFAD mice.
Farfara D; Sooliman M; Avrahami L; Royal TG; Amram S; Rozenstein-Tsalkovich L; Trudler D; Blanga-Kanfi S; Eldar-Finkelman H; Pahnke J; Rosenmann H; Frenkel D
J Neuroinflammation; 2023 Jul; 20(1):174. PubMed ID: 37496076
[TBL] [Abstract][Full Text] [Related]
15. Aberrant expression of the pore-forming K
Griffith CM; Xie MX; Qiu WY; Sharp AA; Ma C; Pan A; Yan XX; Patrylo PR
Neuroscience; 2016 Nov; 336():81-101. PubMed ID: 27586053
[TBL] [Abstract][Full Text] [Related]
16. S100B Inhibitor Pentamidine Attenuates Reactive Gliosis and Reduces Neuronal Loss in a Mouse Model of Alzheimer's Disease.
Cirillo C; Capoccia E; Iuvone T; Cuomo R; Sarnelli G; Steardo L; Esposito G
Biomed Res Int; 2015; 2015():508342. PubMed ID: 26295040
[TBL] [Abstract][Full Text] [Related]
17. Amyloid-β plaque formation and reactive gliosis are required for induction of cognitive deficits in App knock-in mouse models of Alzheimer's disease.
Sakakibara Y; Sekiya M; Saito T; Saido TC; Iijima KM
BMC Neurosci; 2019 Mar; 20(1):13. PubMed ID: 30894120
[TBL] [Abstract][Full Text] [Related]
18. ApoA-I deficiency increases cortical amyloid deposition, cerebral amyloid angiopathy, cortical and hippocampal astrogliosis, and amyloid-associated astrocyte reactivity in APP/PS1 mice.
Button EB; Boyce GK; Wilkinson A; Stukas S; Hayat A; Fan J; Wadsworth BJ; Robert J; Martens KM; Wellington CL
Alzheimers Res Ther; 2019 May; 11(1):44. PubMed ID: 31084613
[TBL] [Abstract][Full Text] [Related]
19. GFAP isoforms in adult mouse brain with a focus on neurogenic astrocytes and reactive astrogliosis in mouse models of Alzheimer disease.
Kamphuis W; Mamber C; Moeton M; Kooijman L; Sluijs JA; Jansen AH; Verveer M; de Groot LR; Smith VD; Rangarajan S; Rodríguez JJ; Orre M; Hol EM
PLoS One; 2012; 7(8):e42823. PubMed ID: 22912745
[TBL] [Abstract][Full Text] [Related]
20. Amyloid-β plaques affect astrocyte Kir4.1 protein expression but not function in the dentate gyrus of APP/PS1 mice.
Huffels CFM; Osborn LM; Hulshof LA; Kooijman L; Henning L; Steinhäuser C; Hol EM
Glia; 2022 Apr; 70(4):748-767. PubMed ID: 34981861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
